Rheumatology
FDA/CDC
FDA approves IL-23 inhibitor risankizumab for treating plaque psoriasis
More than half of patients had total skin clearance after a year of risankizumab treatment.
Conference Coverage
ACE inhibitors may improve neuropsychiatric lupus
SAN FRANCISCO –
Conference Coverage
Bronchiolitis is a feared complication of connective tissue disease
MAUI, HAWAII – “Stability equals success in these patients,” says Aryeh Fischer, MD.
Clinical Review
Management of Cardiovascular Disease Risk in Rheumatoid Arthritis
Conference Coverage
Novel RA strategy: Target first-line biologics for likely methotrexate nonresponders
MAUI, HAWAII – T-cell subset quantification weeds out RA patients unlikely to achieve remission on first-line methotrexate.
News
Death data spur black-box warning for gout drug Uloric
FDA acts after postmarket trial shows higher all-cause and heart-related death when compared against allopurinol.
News
AAD, NPF release two joint guidelines on treatment, management of psoriasis
The next guidelines will address phototherapy, topical therapy, nonbiologic systemic medications, and treatment of pediatric patients.
Conference Coverage
Take action to mitigate CVD risk in RA patients
The mechanisms of increased CVD risk in RA are multifactorial, and risk management strategies should take into account a patient’s apparent risk,...
Conference Coverage
New findings raise questions about the role of ANAs in SLE
Studies suggest that 20%-30% of SLE patients are ANA negative at testing and that there is a great deal of variability across tests, which could...
News
Psoriatic arthritis eludes early diagnosis
Patients with psoriasis have an increased risk for psoriatic arthritis, but diagnosing its onset early poses challenges.